Consultant Ophthalmologist with special interest in Glaucoma, Chorley and South Ribble Hospitals, NHS trust, Chorley, UK.
University of Bolton, Greater Manchester, UK.
Eye (Lond). 2024 Dec;38(17):3357-3361. doi: 10.1038/s41433-024-03307-7. Epub 2024 Aug 28.
Selective laser trabeculoplasty has been carried out at Lancashire Teaching Hospitals over the past seven years. This work aimed to review the use of SLT in this Trust. The primary objectives were to establish the efficacy of SLT in reducing intraocular pressure, to analyse how prior treatment with different topical medications can influence SLT outcomes and to analyse the outcomes in revisionary patients.
We conducted a retrospective review of 288 eyes, with a known history of glaucoma or ocular hypertension and who underwent initial SLT laser treatment between October 2018 and January 2020. SLT was performed on known glaucoma and treatment naïve patients where IOP control was deemed sub-optimal. All patient data was fully anonymised.
We found that SLT was effective in lowering IOP. Around two-thirds of the eyes (181/280, 65%) achieved a reduction in IOP of 10% or more. Just under half (127/280, 45%) achieved a reduction of 20% or more. For a pre-SLT IOP of 14.6 mmHg, we found that no mean change in IOP is expected, and for each 1 mmHg by which the pre-SLT IOP exceeds this threshold, the mean reduction in IOP is expected to be 0.61 mmHg. We also found that combination therapies of PGA plus aqueous suppressants gave better outcomes compared with PGA alone. We found that revisionary SLT compared favourably with the first treatment, although first-time outcomes were not a good predictor of success with revisionary SLT.
Primary and revisionary SLT has been shown to be effective across the cohort of patients in this study.
在过去的七年中,兰开夏教学医院一直在进行选择性激光小梁成形术。这项工作旨在回顾本信托基金中 SLT 的使用情况。主要目标是确定 SLT 在降低眼压方面的疗效,分析不同局部药物治疗的前期治疗如何影响 SLT 结果,并分析复发性患者的结果。
我们对 288 只已知患有青光眼或高眼压症且在 2018 年 10 月至 2020 年 1 月期间接受首次 SLT 激光治疗的眼睛进行了回顾性研究。对已知患有青光眼且未经治疗的患者进行 SLT,这些患者的眼压控制被认为不理想。所有患者数据均完全匿名。
我们发现 SLT 能有效降低眼压。大约三分之二的眼睛(181/280,65%)眼压降低 10%或更多。近一半(127/280,45%)眼压降低 20%或更多。对于 SLT 前的眼压 14.6mmHg,我们发现预计眼压不会有任何变化,而 SLT 前的眼压每超过这个阈值 1mmHg,预计眼压平均降低 0.61mmHg。我们还发现,PGA 加水性抑制剂的联合治疗比 PGA 单独治疗效果更好。我们发现,与第一次治疗相比,复发性 SLT 效果较好,尽管第一次治疗的结果并不能很好地预测复发性 SLT 的成功率。
本研究队列中的患者的原发性和复发性 SLT 均显示有效。